BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 01/05/2012

Determination That GRIFULVIN V (Griseofulvin Microcrystalline) Tablets, 250 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

The Food and Drug Administration (FDA) has determined that GRIFULVIN V (griseofulvin microcrystalline) tablets, 250 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for griseofulvin microcrystalline tablets, 250 mg, if all other legal and regulatory requirements are met.

Source: Federal Register — Food and Drug AdministrationOpen original release →